Orlistat is currently the only prescribed form of pharmacological management for obesity and functions by reducing the amount of fat absorbed from food eaten. Although frequently prescribed, there is marked variability in outcomes. A total of 10 participants’ experiences of gaining weight after taking orlistat were analysed using thematic analysis. Participants attributed their failed weight loss to mechanisms of the medication, emphasised a medical model of obesity with barriers to their weight loss and other weight-loss methods which had also failed. Overall, their weight gain was considered an inevitable part of their self-identity, reflecting their self-fulfilling prophecy of being a perpetual dieter.
BraunVClarkeV (2006) Using thematic analysis in psychology. Qualitative Research in Psychology3(2): 77–101.
3.
BrownellKDRodinJ (1994) Medical, metabolic, and psychological effects of weight cycling. Archives of Internal Medicine154(12): 1325–1330.
4.
EpiphaniouEOgdenJ (2010) Successful weight loss maintenance and a shift in identity: From restriction to a new liberated self. Journal of Health Psychology15: 887–896.
5.
FrenchSAJeffreyRW (1997) Current dieting, weight loss history and weight suppression: Behavioural correlates of three dimensions of dieting. Addictive Behaviors22: 31–44.
6.
HollywoodAOgdenJ (2011) Taking orlistat: Predicting weight loss over 6 months. Journal of Obesity2011: 806896.
7.
JebbSAGoldbergGRCowardWA. (1991) Effects of weight cycling caused by intermittent dieting on metabolic rate and body composition in obese women. International Journal of Obesity15(5): 367–374.
8.
KelleyHH (1971) Attribution: Perceiving the Causes of Behaviour. New York: General Learning Press.
9.
KrokeALieseADSchulzM. (2002) Recent weight changes and weight cycling as predictors of subsequent two year weight change in a middle-aged cohort. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity26(3): 403–409.
10.
LeventhalHMeyerDNerenzD (1980) The common sense representation of illness danger. Medical Psychology2: 7–30.
11.
LissnerLBengtssonCLapidusB, et al. (1989) Body weight variability and mortality in the Gothenburg Prospective Studies of men and women. In: BjorntorpPRossnerS (eds) Obesity in Europe 88: Proceedings of the First European Congress on Obesity. London: John Libbey Publishing, pp. 55–60.
12.
National Institute for Clinical Excellence (2001) Technology appraisal guidance no. 22: Guidance on the use of orlistat for the treatment of obesity in adults. London: National Institute for Clinical Excellence.
13.
OgdenJ (2000) The correlates of long term weight loss: A group comparison study of obesity. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity24: 1018–1025.
14.
OgdenJFlannaganZ (2008) Beliefs about the causes and solutions to obesity: A comparison of GPs and lay people. Patient Education and Counselling71: 72–78.
15.
OgdenJHillsL (2008) Understanding sustained changes in behaviour: The role of life events and the process of reinvention. Health: An International Journal12: 419–437.
16.
OgdenJSidhuS (2006) Adherence, behavior change, and visualization: A qualitative study of the experiences of taking an obesity medication. Journal of Psychosomatic Research61: 545–552.
17.
OgdenJBandaraICohenH. (2001) General practitioners’ and patients’ models of obesity: Whose problem is it?Patient Education and Counselling44: 227–233.
18.
PadwalRLiSKLauDCW (2003) Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity27: 1437–1446.
19.
Royal College of Physicians of London (2003) Anti-obesity drugs: guidance on appropriate prescribing and management, A report of the Nutrition Committee of the Royal College of Physicians ofLondon, April.
20.
RuckerDPadwalRLiSK. (2007) Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ335: 1194–1199.
21.
SrishanmuganathanJPatelHCarJ. (2007) National trends in the use and costs of anti-obesity medications in England 1998–2005. Journal of Public Health29: 199–202.
22.
VrayMJoubertJMEschwègeE. (2005) Results from the observational study EPIGRAM: Management of excess weight in general practice and follow-up of patients treated with orlistat. Therapie60: 17–24.
23.
WilliamsGCGrowVMFreedmanZR. (1996) Motivational predictors of weight loss and weight loss maintenance. Journal of Personality and Social Psychology70: 115–126.
